🇺🇸 Calcineurin Inhibitor in United States
30 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 30
Most-reported reactions
- Cytomegalovirus Infection — 4 reports (13.33%)
- Disease Recurrence — 4 reports (13.33%)
- Acute Graft Versus Host Disease — 3 reports (10%)
- Anaemia — 3 reports (10%)
- Ascites — 3 reports (10%)
- Neurotoxicity — 3 reports (10%)
- Off Label Use — 3 reports (10%)
- Vomiting — 3 reports (10%)
- Acute Hepatic Failure — 2 reports (6.67%)
- Blood Creatinine Increased — 2 reports (6.67%)
Other Immunology approved in United States
Frequently asked questions
Is Calcineurin Inhibitor approved in United States?
Calcineurin Inhibitor does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Calcineurin Inhibitor in United States?
Milton S. Hershey Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.